The revision of the EU Regulations on medicines for children and for rare diseases

The revision of the EU legislation on medicines for rare diseases and for children is one of the key actions of the Pharmaceutical Strategy for Europe. Our joint policy dialogue organised with the European Society for Paediatric Oncology, European Fair Pricing Network and the Association of European Cancer Leagues discussed concrete recommendations to deliver optimal treatment for children and those suffering from rare diseases, as ”one-size-fits-all” incentives do not lead to a sustainable and equitable pharmaceutical system.